Диабетическая ретинопатия: современные подходы к ведению пациентов

1. Астахов Ю.С., Шадричев Ф.Е. Диабетологические центры – новый этап в создании специализированной помощи больным с диабетической ретинопатией. Клин. офтальмология. 2001; 4: 148–53.
2. Астахов Ю.С., Шадричев Ф.Е., Лисочкина А.Б. Лазеркоагуляция сетчатки при лечении диабетической ретинопатии. Клин. офтальмология. 2000; 1 (1): 15–8.
3. Шадричев Ф.Е. Протокол офтальмологического ведения больных сахарным диабетом. Офтальмологические ведомости. 2008; 1 (2): 54–61.
4. Шадричев Ф.Е., Рахманов В.В., Григорьева Н.Н., Шкляров Е.Б. Почему фенофибрат может снижать риск прогрессирования диабетической ретинопатии у больных сахарным диабетом 2 типа. Офтальмологические ведомости. 2010; 3 (2): 53–60.
5. Шадричев Ф.Е., Шкляров Е.Б., Григорьева Н.Н. Использование анти-VEGF терапии в лечении диабетического макулярного отека. Офтальмологические ведомости. 2011; 
4 (1): 83–93.
6. Шадричев Ф.Е., Шкляров Е.Б., Григорьева Н.Н. Применение кортикостероидов в лечении диабетического макулярного отека. Офтальмологические ведомости. 2011; 4 (2): 76–88.
7. Шадричев Ф.Е., Шкляров Е.Б., Григорьева Н.Н. Скрининг диабетической ретинопатии: от офтальмоскопии к цифровому фотографированию. Офтальмологические ведомости. 2009; 2 (4): 19–30.
8. The ACCORD Study Group and ACCORD Eye Study Group. Effect of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010; 363 (3): 233–43.
9. Colhoun HM, Betteridge DJ, Durrington PN et al. On behalf of the CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatine Diabetes Study (CARDS): multicenter randomized placebo-controlled trial. Lancet 2004; 364: 685–96.
10. Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complication in insulin dependent diabetes mellitus. N Engl J Med 1993; 329: 977–86.
11. Diabetes Control and Complication Trial Research Group. The relationship of glycemic exposure (HbA1с) to the risk of development and progression of retinopathy in the Diabetes Control and Complication Trial. Diabetes 1995; 44: 968–83.
12. Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117 (6): 1064–77.
13. Diabetic Retinopathy Study Research Group. Report No 8. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of diabetic retinopathy study (DRS) findings. Ophthalmology 1981; 88: 583–600.
14. Diabetic Retinopathy Research Group. Report No 14. Indications for photocoagulation treatment of diabetic retinopathy. Int Ophthalmol Clin 1987; 27: 239–52.
15. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report No 9. Ophthalmology 1991; 98: 766–85.
16. Jaeger E. Beiträge zur Pathologie des Auges.Wien, 1855–1856.
17. Keech AC, Mitchell P, Summanen PA et al. FIELD study investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007; 370: 1687–97.
18. Keech AC, Simes RJ, Barter P et al. FIELD study investigators. Effect of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849–61.
19. Klein R, Klein BEK, Moss SE et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalol 1984; 102: 520–6.
20. Klein R, Klein BEK, Moss SE et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984: 102: 527–32.
21. Klein R, Klein BEK, Moss SE et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XI. The incidence of macular edema. Ophthalmology 1989; 96: 1501–10.
22. Mackenzie S, Nettleship E. A case of glycosuric retinitis. Roy Ophth Lond Hosp Rep IX 1877: 134.
23. Manz W. Retinitis proliferans. Graefes Arch Clin Exp Ophthalmol 1876; 22: 229.
24. Massin P, Bandello F, Garweg JG et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010; 33 (11): 2399–405.
25. Mitchell P, Bandello F, Schmidt-Erfurth U. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118 (4): 615–25.
26. Nettleship E. On oedema or cystic disease of the retina. Roy Ophth Lond Hosp Rep VII 1872: 343–51.
27. Noyes HD. Retinitis in glycosuria. Trans Am Ophthalmol Soc 1869; 4: 71–5.
28. Porta M, Kohner EM, Screening for diabetic retinopathy in Europe. Diabetic Medicine 1991; 8: 197–8.
29. Stephenson J, Fuller JH and EURODIAB IDDM Complications Study. Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study. Diabetologia 1994; 37: 278–85.
30. Stratton IM, Kohner EM, Aldington SJ et al. UKPDS 50: risk factors for incidence and progression of diabetic retinopathy in type 2 diabetes over 6 years from diagnosis. Diabetologia 2001; 44: 156–63.
31. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes: UKPDS 33. Lancet 1998; 352: 837–53.
32. WHO/IDF Europe. Diabetes Care and Research in Europe: the St Vinsent Declaration. Diabetic Medicine 1990; 7: 360.
33. WHO. Prevention of blindness from diabetes mellitus. Report of a WHO consultation in Geneva 9–11 November 2005. Switzerland. WHO press, 2005.

Ф.Е.Шадричев 

Санкт-Петербургский территориальный диабетологический центр